TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7573718

Group type: EXPERIMENTAL
Intervention: Artemether (AR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Quinine (QN)
Number of subjects: 13
Study: 1664346

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 x 4 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 7066139

Group type: EXPERIMENTAL
Intervention: i.m. morphine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: self-administered i.v. pethidine
Number of subjects: 126
Study: 30407996

Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac (IVK)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no IVK)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 27787671

Group type: EXPERIMENTAL
Intervention: Child intervention condition
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Child + parent intervention condition
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 267
Study: 26313301

Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 24760263

Group type: EXPERIMENTAL
Intervention: Shape- and pressure-based orthoses (experimental)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard-of-care A5513 orthoses (control)
Number of subjects: 130
Study: 23159967

Group type: EXPERIMENTAL
Intervention: Migraine treatment and H. pylori eradication treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Migraine treatment and placebo (control)
Number of subjects: 64
Study: 20069517

Group type: EXPERIMENTAL
Intervention: Standardized back school programme
Number of subjects: 360
Study: 17303309

Group type: EXPERIMENTAL
Intervention: CPR training/retraining
Number of subjects: 2729

Group type: EXPERIMENTAL
Intervention: AED training/retraining
Number of subjects: 2729

Group type: COMPARATOR
Intervention: Further retraining intervals (3, 6, 9, and 12 months)
Number of subjects: 2729
Study: 15902596

Group type: EXPERIMENTAL
Intervention: Interactive pc‐based training program
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Training in outpatient clinics
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Small group training during inpatient stay
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: MDI phantoms
Number of subjects: 125

Group type: COMPARATOR
Intervention: Suppliers medication leaflet
Number of subjects: 125
Study: 12436350

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 10628247

Group type: EXPERIMENTAL
Intervention: Local application of procaine spirit
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cleansing with water (Control)
Number of subjects: 100
Study: 7720296

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (100 mcg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2119419

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pravastatin + resins
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of pravastatin and resins
Number of subjects: 40
Study: 7435893

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg in a single dose prior to bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving saline
Number of subjects: 0
Study: 29073688

Group type: EXPERIMENTAL
Intervention: Ambient temperature of 34°C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambient temperature of 28°C
Number of subjects: 0
Study: 26657442

Group type: COMPARATOR
Intervention: NHS-funded patient
Number of subjects: 119

Group type: COMPARATOR
Intervention: Privately-funded patient
Number of subjects: 119

Group type: COMPARATOR
Intervention: Undisclosed-fee patient
Number of subjects: 119
Study: 23473342

Group type: EXPERIMENTAL
Intervention: meloxicam (1 mg/kg PO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: gabapentin (15 mg/kg PO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: meloxicam (1 mg/kg) and gabapentin (15 mg/kg) PO
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: flunixin (2.2 mg/kg IV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 22331114

Group type: EXPERIMENTAL
Intervention: Ganciclovir 0.15% ophthalmic gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: Artificial tears without preservative
Number of subjects: 33
Study: 19487950

Group type: EXPERIMENTAL
Intervention: 1 g i.v. paracetamol 20 min before and 4, 10 and 16 h after the end of the operation.
Number of subjects: 87

Group type: COMPARATOR
Intervention: 1 g i.v. metamizol scheduled at the same time points as paracetamol.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo scheduled at the same time points as paracetamol.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 1 g i.v. paracetamol
Number of subjects: 87

Group type: COMPARATOR
Intervention: 1 g i.v. metamizol
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17160693

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg BID for 2 weeks escalating to 40 mg BID for 6 weeks
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg BID for 8 weeks
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg QD for 2 weeks escalating to 40 mg BID for 6 weeks
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Duloxetine (any regimen)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study: 12892566

Group type: EXPERIMENTAL
Intervention: Spinal manipulation plus best care in general practice
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Exercise classes (Back to Fitness) plus best care in general practice
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Spinal manipulation followed by exercise plus best care in general practice
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Best care in general practice only
Number of subjects: 1350
Study: 11145489

Group type: EXPERIMENTAL
Intervention: Eptifibatide (two 180 microg/kg boluses 10 min apart and a continuous infusion of 2.0 microg/kg/min for 18‐24 h)
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study: 9529558

Group type: EXPERIMENTAL
Intervention: Topically applied antioxidants (combinations of alpha‐glycosylrutin, ferulic acid, and tocopheryl acetate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle only (control group)
Number of subjects: 30
Study: 14628737

Group type: EXPERIMENTAL
Intervention: Human interferon-beta (HuIFN-beta)
Number of subjects: 30
Study: 2988393

Group type: COMPARATOR
Intervention: Improved diet in calcium and Vitamin D (Group I)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intramuscular supplement of 30 mg of Vitamin D3 in monthly injections of 5 or 10 mg (Group II)
Number of subjects: 28
Study: 29754530

Group type: EXPERIMENTAL
Intervention: 23 mmHg medical compression stockings (group A)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 35 mmHg medical compression stockings (group B)
Number of subjects: 94
Study: 29462997

Group type: EXPERIMENTAL
Intervention: Fibroin protein enzymatic hydrolysate (FPEH) at doses of 280 mg, 400 mg, and 600 mg per day for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 mg FPEH)
Number of subjects: 0
Study: 26725694

Group type: EXPERIMENTAL
Intervention: Tele-nursing follow-up interventions and nursing education
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine interventions (Control)
Number of subjects: 71
Study: 25826729

Group type: EXPERIMENTAL
Intervention: 12-week intervention consisting of a very-low-energy diet for the initial 6 weeks followed by a hypocaloric diet, combined with a weekly group multidisciplinary programme (n=27)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group receiving recommendations for weight loss and the same printed material (n=22)
Number of subjects: 49
Study: 22991952

Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Alert (PAAL) intervention
Number of subjects: 300
Study: 19825849

Group type: EXPERIMENTAL
Intervention: 80 mg IM methylprednisolone acetate
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 18953215

Group type: EXPERIMENTAL
Intervention: HRA plus targeted disease management (DM group)
Number of subjects: 133

Group type: COMPARATOR
Intervention: HRA plus information about worksite health promotion programs (HRA group)
Number of subjects: 133
Study: 16428154

Group type: COMPARATOR
Intervention: Oral terbinafine 250 mg/day for 16 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of oral terbinafine 250 mg/day for 16 weeks and topical ciclopirox nail lacquer once daily for 9 months
Number of subjects: 80
Study: 12598341

Group type: EXPERIMENTAL
Intervention: LV + 5‐FU + RT (Group A)
Number of subjects: 207

Group type: COMPARATOR
Intervention: LV + 5‐FU + RT + IFN‐alpha (Group B)
Number of subjects: 207
Study: 10378089

Group type: EXPERIMENTAL
Intervention: DMSA (2,3 dimercaptosuccinic acid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8892765

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program (3 sessions per week for 12 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program + calcium heparin 12,500 IU subcutaneously 20 to 30 minutes before each exercise session
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 36
Study: 1845132

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (15-1000 micrograms/m2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: rhIL-3 (60 micrograms/m2, s.c.)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: rhEPO (10,000 U five times weekly or 150-450 U/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (250 g/m2/day x 14, s.c.) combined with Ara-C (20 mg/m2/day x 14, s.c.)
Number of subjects: 65
Study: 6365209

Group type: EXPERIMENTAL
Intervention: T-CAF (cyclophosphamide, adriamycin, and 5-fluorouracil plus tamoxifen)
Number of subjects: 232

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, and 5-fluorouracil)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: T-CAF
Number of subjects: 232

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 232
Study: 30081019

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg body weight, administered intravenously at weeks 0, 4, 8, and 12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 32
Study: 27282848

Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 585

Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 585
Study: 24385141

Group type: EXPERIMENTAL
Intervention: Treatment with antioxidant vitamins and minerals
Number of subjects: 4757
Study: 22196768

Group type: EXPERIMENTAL
Intervention: 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg of PF-03654746 plus 60 mg of fexofenadine (group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60 mg of fexofenadine/120 mg of pseudoephedrine (group 3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 20
Study: 20307797

Group type: EXPERIMENTAL
Intervention: Prize draw incentive program (up to $400 over 3 months)
Number of subjects: 803
Study: 18566198

Group type: EXPERIMENTAL
Intervention: TIVA propofol for 5 minutes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TIVA propofol for 20 minutes
Number of subjects: 28
Study: 15776773

Group type: EXPERIMENTAL
Intervention: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac) in combination with oral doxycycline hyclate (Doryx) and adapalene gel (Differin)
Number of subjects: 0
Study: 12005454

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid-based lipid emulsion (fish oil, 10%; 200 mL/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: n-6 lipid emulsion (soybean oil, 10%; 200 mL/d)
Number of subjects: 22
Study: 10404344

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg od
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg od
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cefuroxime axetil 250 mg bd
Number of subjects: 124
Study: 7562275

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula (group We)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amino acid-derived formula (group AA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Breast-fed control infants
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both formulas (group We and group AA)
Number of subjects: 74
Study: 2332608

Group type: EXPERIMENTAL
Intervention: 20 mg of prazepam in liquid drops
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 mg of prazepam in tablets
Number of subjects: 10
Study: 7266731

Group type: EXPERIMENTAL
Intervention: Choline chloride (2 g QID)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31928963

Group type: EXPERIMENTAL
Intervention: 100 mg sitagliptin daily for 3 consecutive cycles
Number of subjects: 38

Group type: COMPARATOR
Intervention: Identical placebo capsules
Number of subjects: 38
Study: 30053213

Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 10
Study: 28595613

Group type: EXPERIMENTAL
Intervention: Multimedia information resource in conjunction with standard participant information sheets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia information resource alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard participant information sheets alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia information resources
Number of subjects: 0
Study: 25728152

Group type: EXPERIMENTAL
Intervention: Novel silver-impregnated Foley catheter system
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control system
Number of subjects: 95
Study: 23531689

Group type: EXPERIMENTAL
Intervention: Aquatic exercise group (AEG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study: 21317776

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study: 18707776

Group type: EXPERIMENTAL
Intervention: Self-report psychosocial measures
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Structured clinical interviews
Number of subjects: 280
Study: 17006780

Group type: EXPERIMENTAL
Intervention: PECS intervention group (15 h of PECS teaching over 5 weeks)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non‐intervention control group (no PECS teaching)
Number of subjects: 2
Study: 15365580

Group type: EXPERIMENTAL
Intervention: Fluoxetine or desipramine (active treatment) for 8 weeks
Number of subjects: 80
Study: 11548133

Group type: EXPERIMENTAL
Intervention: 7-week behaviorally based telephone and mail intervention promoting walking for exercise
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-behavioral minimal intervention
Number of subjects: 102
Study: 10874061

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy guided by electrophysiologic testing
Number of subjects: 1750

Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Registry patients (no inducible tachyarrhythmias)
Number of subjects: 1750
Study: 9175963

Group type: EXPERIMENTAL
Intervention: ropivacaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 12
Study: 1552468

Group type: EXPERIMENTAL
Intervention: Minocycline periodontal formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo periodontal formulation
Number of subjects: 0
Study: 3874932

Group type: COMPARATOR
Intervention: High-dose methotrexate with citrovorum factor rescue (MTX-CF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-arterial cis-diamminedichloroplatinum II (I/A-CDP)
Number of subjects: 30
Study: 31226342

Group type: EXPERIMENTAL
Intervention: Informational tweets
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Organizational senders
Number of subjects: 782

Group type: COMPARATOR
Intervention: Personal experience tweets
Number of subjects: 782

Group type: COMPARATOR
Intervention: Rare personal experience messages
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Messages using organizational senders and factual information
Number of subjects: 782
Study: 29356820

Group type: EXPERIMENTAL
Intervention: Web-based platform
Number of subjects: 459

Group type: COMPARATOR
Intervention: Genetic counselor
Number of subjects: 459
Study: 26483177

Group type: EXPERIMENTAL
Intervention: 300 mg of omalizumab
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: 75 mg of omalizumab
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: 150 mg of omalizumab
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study: 24567516

Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg once weekly (CIL1W) + PFE
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg twice weekly (CIL2W) + PFE
Number of subjects: 182

Group type: COMPARATOR
Intervention: PFE alone
Number of subjects: 182
Study: 23113436

Group type: EXPERIMENTAL
Intervention: Mission Essential Fitness (MEF) circuit-style training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Army Physical Readiness Training (APRT)
Number of subjects: 67
Study: 20158298

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CACR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention control condition (CATT)
Number of subjects: 160
Study: 19226890

Group type: EXPERIMENTAL
Intervention: Acupuncture plus Ligustrazine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ligustrazine
Number of subjects: 86
Study: 16213325

Group type: EXPERIMENTAL
Intervention: CsA-based treatment (n = 73)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based treatment (n = 47)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Conversion from CsA to tacrolimus (n = 35)
Number of subjects: 155
Study: 11947912

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 58
Study: 11370581

Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 (Monocryl) used in 136 cases
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Glycomer 631 (Biosyn) used in 116 cases
Number of subjects: 178
Study: 8574272

Group type: EXPERIMENTAL
Intervention: ICI D7114 (150 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2301986

Group type: EXPERIMENTAL
Intervention: Artificial food colours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31694653

Group type: EXPERIMENTAL
Intervention: Leap Motion Controller® (LMC) system with serious games for upper limb rehabilitation (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Specific intervention for upper limb rehabilitation (n=11)
Number of subjects: 23
Study: 28196486

Group type: EXPERIMENTAL
Intervention: Integrated care at home (additional home evaluation by a community geriatrics unit with access to a call service and coordinated follow-up)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Integrated care at home
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 301
Study: 26095227

Group type: EXPERIMENTAL
Intervention: Body checking behaviour
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control condition (randomized computer-emitted acoustic signals)
Number of subjects: 55
Study: 23677386

Group type: EXPERIMENTAL
Intervention: In SHAPE program (one year of weekly sessions with a fitness trainer plus a fitness club membership)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fitness club membership and education (control)
Number of subjects: 133
Study: 20815720

Group type: EXPERIMENTAL
Intervention: Early soft palate repair in infants with unilateral cleft lip and palate (UCLP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (typically developing children without clefts)
Number of subjects: 41
Study: 19264687

Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg administered in five monthly infusions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 20
Study: 17889778

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15466264

Group type: EXPERIMENTAL
Intervention: BQ‐123
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BQ‐123 + E (enalapril)
Number of subjects: 6
Study: 11575287

Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation of the subthalamic nucleus
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation of the pars interna of the globus pallidus
Number of subjects: 134
Study: 9643742

Group type: EXPERIMENTAL
Intervention: rhGH (2 IU daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 50
Study: 7838582

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cognitive self-hypnosis training (CSH)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: High-hypnotizable subjects (AT or CSH)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Low-hypnotizable subjects (AT or CSH)
Number of subjects: 146
Study: 3169118

Group type: EXPERIMENTAL
Intervention: cimetidine (1.2 g daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ranitidine (0.3 g daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8